Amniotic Membrane Transplantation in Acute Severe Ocular Chemical Injury: A Randomized Clinical Trial

Acknowledgments/disclosure a. Funding/Support: This work was partially supported by R01 EY024349 (ARD) and Core Grant for Vision Research P30 EY001792 from NEI/NIH; Vision for Tomorrow (ARD), and unrestricted grant to the department from Research to Prevent Blindness (all located in the US). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. b. Financial Disclosures: No financial disclosures for ME, AB, AYC, KHK, HH, and ARD. The authors have no financial interest in the products discussed and did not receive funding for any of the work. EJH has consulted for Alcon Laboratories, Allergan, Bausch & Lomb, Katena, Kala Pharmaceuticals, Mati Pharmaceuticals, Omeros, PRN, TearLab, TearScience, Senju Pharmaceuticals, and Shire (all located in the US). All authors attest that they meet the current ICMJE criteria for authorship.